Related Experiment Video
Updated: Jul 23, 2026
09:22
A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning
Published on: June 22, 2015
[Preclinical study of noopept toxicity]
L P Kovalenko1, N M Smol'nikova, S V Alekseeva
1Laboratory of Drug Toxicology, Institute of Pharmacology, Russian Academy of Medical Sciences, Baltiiskaya ul. 8, Moscow, 125315 Russia.
Eksperimental'Naia I Klinicheskaia Farmakologiia
|May 25, 2002
Summary
Noopept, a novel nootropic, demonstrated safety in a 6-month preclinical study. It showed no toxic effects and did not impair reproductive or developmental functions in rabbits.
Area of Science:
- Pharmacology
- Toxicology
- Immunology
Background:
- Noopept (N-phenyl-acetyl-L-propyl-glycine ethylate) is a new nootropic agent.
- Preclinical safety and efficacy data are crucial for drug development.
Purpose of the Study:
- To evaluate the chronic toxicity of noopept in a preclinical setting.
- To assess the immunomodulatory effects of noopept.
Main Methods:
- Chronic oral administration of noopept (10 or 100 mg/kg) to male and female rabbits for 6 months.
- Assessment of pathological changes, reproductive function, and progeny development.
- Evaluation of immune response in mice using concanavalin A stimulation.
Main Results:
- Noopept did not induce irreversible pathological changes in rabbits at tested doses.
- No allergenic, immunotoxic, or mutagenic activity was observed.
- Noopept suppressed inflammation and stimulated cellular and humoral immune responses in mice.
Conclusions:
- Noopept exhibits a favorable safety profile for chronic use.
- Noopept possesses immunomodulatory properties, with potential therapeutic applications.
More Related Videos
Related Concept Videos
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:23Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...